Polymeric nanocarriers for the treatment of systemic iron overload
| Autor: | Jasmine L. Hamilton, Jayachandran N. Kizhakkedathu |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
Economics and Econometrics media_common.quotation_subject Desferasirox Nanotechnology Review Pharmacology Polymeric chelators Long circulating 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Materials Chemistry Media Technology Iron overload Medicine Deferiprone Drug toxicity Nanomaterials 030304 developmental biology media_common Iron chelators Iron Chelator 0303 health sciences business.industry Polymeric nanocarriers Desferrioxamine Forestry Iron chelation therapy 3. Good health chemistry 030220 oncology & carcinogenesis Toxicity business |
| Zdroj: | Molecular and cellular therapies |
| ISSN: | 2052-8426 |
| DOI: | 10.1186/s40591-015-0039-1 |
| Popis: | Desferrioxamine (DFO), deferiprone (L1) and desferasirox (ICL-670) are clinically approved iron chelators used to treat secondary iron overload. Although iron chelators have been utilized since the 1960s and there has been much improvement in available therapy, there is still the need for new drug candidates due to limited long-term efficacy and drug toxicity. Moreover, all currently approved iron chelators are of low molecular weight (MW) ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink